Nexxen to Announce Fourth Quarter 2023 Financial Results on March 6, 2024
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) — Nexxen International Ltd. (AIM/NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, unified […]
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Three Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in 2024 Announced First Human Proof-of-Concept Data for In Vivo Base […]
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) today announced the issuance of three […]
Tourmaline Bio to Present at Upcoming Investor Conferences
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative […]
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology […]
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE®(pegcetacoplan injection) and $91 million for EMPAVELI®(pegcetacoplan) Strong […]
Sotera Health Reports Fourth-Quarter and Full-Year 2023 Results; Provides 2024 Outlook
2023 net revenues increased 4.5% to $1.05 billion, compared to 2022 2023 net income of $51 million or $0.18 per […]
ChampionX acquires Artificial Lift Performance Limited to expand digital solutions portfolio
THE WOODLANDS, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) — ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) announced today the […]
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving […]
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase […]
